



# **SITUATION REPORT**

Nigeria Centre For Disease Control (NCDC)

NCDC.GOV.NG	PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA <b>TOLL FREE CALL:</b> 6232 <b>E:</b> info@ncdc.gov.ng	@NCD	Cgov 🖪
TITLE:	UPDATE ON MPOX (MPX) IN NIGERIA		
SERIAL NUMBER:	39		
EPI-WEEK:	39		
DATE:	October 1, 2023		

## Table 1 – Key Indicators

Reporting Year	Reporting week	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023 Current	Week 39	8	0	0	0.0	0	0
2023 Cumulative	Week 39	956	80	2	2.5	19 +FCT	52
2022 Cumulative	Week 39	1188	484	7	1.4	30 + FCT	189

# Highlights

- In week 39, the number of new suspected cases is 8, compared with 11 cases reported in week 38, 2023. These were reported from five (5) States Delta (3), Ogun (2), Oyo (1), Imo (1) and Lagos (1) across 5 Local Government Areas.
- Since week 1 of 2023, nineteen (1) States and FCT have recorded at least one confirmed Mpox case across fifty-two (52) Local Government Areas. In 2023, the States with the highest burden are Lagos (27.8%), Ogun (19.0%), Abia (7.6%), Imo (6.3%) and Edo (5.1%), contributing 66.7% of confirmed cases.
- The number of confirmed cases is zero (0) in week 39, 2023, the same as zero (0) confirmed cases reported in week 38, 2023.
- No death was recorded in week 39, with a CFR of 0.0%, the same as the CFR of 0.0% that was reported in week 38, 2023.
- Overall, since the re-emergence of Mpox in September 2017, 3550 suspected cases have been reported from 36 States and the FCT in the country. Of these 3550 suspected cases, 1068 (30.2%) were confirmed (with males predominantly affected) from 34 States and FCT. seventeen (17) deaths have been recorded since the re-emergence in 2017.
- The National Mpox multi-partner, multi-sectoral Technical Working Group (TWG) continues to coordinate the response activities at all levels.












10



**Epidemiological weeks** 





No of Cases

CDC

CINERAL Breakthr

Figure 2: Age and sex distribution of Nigeria confirmed monkeypox cases from January 2023 till date.






Figure 3: Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2023 till date.




Figure 4: Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 1<sup>st</sup> October 2023.

eHealth

AFENET AFRICA CDC

Norld Health

CDC

USAID Breakthrough

Table 1: Summary statistics for annual Nigeria Mpox cases by reporting year, September 2017 – 1<sup>st</sup> October 2023

Reporting year	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023	806	80	2	2.5	19 +FCT	52
2022	2123	762	7	0.9	34 + FCT	238
2021	98	34	0	0.0	8 + FCT	25
2020	35	8	0	0.0	5	7
2019	65	47	1	2.1	11	26
2018	116	49	1	2.0	13	25
2017	198	88	6	6.8	14 + FCT	33

Table 2: Age distribution of cumulative number of confirmed Mpox cases September 2017 – 1<sup>st</sup> October 2023

Age Group	2017	2018	2019	2020	2021	2022	2023	Total
0-10 Years	7	5	1	0	1	125	11	150
11-20 Years	12	4	1	0	4	123	6	150
21-30 Years	34	13	13	4	10	187	22	283
31- 40 Years	26	17	22	4	13	205	20	307
41-50 Years	9	10	9	0	5	89	17	139
> 50 Years	0	0	1	0	1	33	4	39
Total	88	49	47	8	34	762	80	1068

Table 3: Nigeria confirmed Mpox cases by State, September 2017 – 1<sup>st</sup> October 2023

S/N	State	2017	2018	2019	2020	2021	2022	2023	Total
1	Lagos	4	1	15	4	6	188	22	240
2	Rivers	25	14	7	1	5	37	4	93
3	Bayelsa	19	11	7	0	6	45	2	90
4	Abia	1	2	0	0	0	58	6	67
5	Delta	3	6	10	1	9	31	1	61
6	Imo	5	2	1	0	0	45	5	58
7	Ogun	0	0	0	0	1	40	15	56
8	Ondo	0	0	0	0	0	40	2	42
9	Edo	4	1	1	0	4	27	4	41
10	FCT	5	0	0	0	1	25	3	34
11	Anambra	0	1	1	0	0	25	0	27
12	Cross River	9	3	1	0	1	12	1	27
13	Kwara	0	0	0	0	0	21	0	21
14	Plateau	0	2	0	1	0	16	0	19
15	Akwa Ibom	6	0	1	0	0	12	3	22
16	Nasarawa	1	1	0	0	0	17	1	20
17	Adamawa	0	0	0	0	0	16	0	16
18	Оуо	1	3	2	0	0	10	1	17
19	Kaduna	0	0	0	0	0	15	2	17
20	Ebonyi	0	0	0	1	0	12	0	13
21	Benue	2	0	0	0	0	10	0	12
22	Borno	0	0	0	0	0	11	2	13
23	Enugu	1	2	1	0	0	4	3	11
24	Katsina	0	0	0	0	0	8	0	8
25	Taraba	0	0	0	0	0	7	0	7

26	Kano	0	0	0	0	0	7	0	7
27	Gombe	0	0	0	0	0	6	0	6
28	Kogi	0	0	0	0	0	5	2	7
29	Osun	0	0	0	0	0	5	0	5
30	Ekiti	2	0	0	0	0	1	0	3
31	Niger	0	0	0	0	1	1	1	3
32	Kebbi	0	0	0	0	0	2	0	2
33	Bauchi	0	0	0	0	0	1	0	1
34	Zamfara	0	0	0	0	0	1	0	1
35	Yobe	0	0	0	0	0	1	0	1
	Grand Total	88	49	47	8	34	762	80	1068

#### **Response activities**

Pillar	Activities to date	Next steps
Coordination	<ul> <li>Facilitating the smooth running of the weekly Mpox technical working group meetings</li> <li>Providing offsite subnational support to resolve issues in reporting States</li> </ul>	<ul> <li>Follow-up implementation of the approved Incident Action plan activities in collaboration with other pillars</li> </ul>
Surveillance	<ul> <li>Eight (8) suspected Mpox cases were reported from 5 States</li> <li>No confirmed case was recorded</li> </ul>	<ul> <li>Continue to support all State Surveillance teams to ensure on SORMAS</li> </ul>
Laboratory	<ul> <li>The sample positivity rate for Mpox is 0% and 50% for Varicella-Zoster Virus (VZV)</li> <li>0% of samples met the target overall turnaround time (time sample was collected from the States to the time when the result was shared with the States)</li> </ul>	<ul> <li>Continue to support effective sample management and transportation to the NRL from health facilities across the country</li> </ul>

#### Notes on this report.

#### Data Source

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.

## **Case definitions**

Suspected case

 An acute illness with fever >38.3°C, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed one to three days later by a progressively developing rash often beginning on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms of the hand.

## Probable case

• A case that meets the clinical case definition is not laboratory-confirmed but has an epidemiological link to a confirmed case.

## Confirmed case.

• A clinically compatible case that is laboratory confirmed





#### Contact

• Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., contact with skin lesions, oral secretions, urine, faeces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

## Calculations

• Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.





